VC life sciences and biotech

About US$80bn worth of pharmaceutical sales will face patent expiration by 2009 forcing the pharmaceutical giants to feed their hungry product pipelines as drugs go generic. This would seem to be good news for biotech and biopharmaceutical companies, but in practice it is becoming more challenging than ever to succeed.